lobbying_activities: 2273486
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2273486 | 31fda5d5-1fed-4da1-b0da-c2332741ddce | Q1 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 31348 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 2019 | first_quarter | PHA | Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE | 1492460 | 0 | 0 | 2019-04-18T15:30:44.147000-04:00 |